KAPOSI SARCOMA
Clinical trials for KAPOSI SARCOMA explained in plain language.
Never miss a new study
Get alerted when new KAPOSI SARCOMA trials appear
Sign up with your email to follow new studies for KAPOSI SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug combo tested for rare skin cancer – but study never started
Disease control TerminatedThis study aimed to test a combination of two drugs, pembrolizumab and lenvatinib, in people with classic Kaposi sarcoma whose cancer had returned or not responded to prior chemotherapy. The goal was to see if the combination could shrink tumors better than standard chemotherapy.…
Matched conditions: KAPOSI SARCOMA
Phase: PHASE2 • Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Disease control
Last updated Jun 17, 2026 01:28 UTC
-
New drug combo shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-phase trial tested a combination of two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), in 62 adults with advanced or hard-to-treat Kaposi sarcoma, a cancer often linked to HIV. The main goals were to check the safety …
Matched conditions: KAPOSI SARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
Hidden bone loss: HIV and cancer patients under the scanner
Knowledge-focused OngoingThis study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…
Matched conditions: KAPOSI SARCOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 17, 2026 01:42 UTC
-
New study aims to personalize kaposi sarcoma treatment in africa
Knowledge-focused OngoingThis study is observing 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa to understand why some respond better to standard chemotherapy than others. Participants receive either paclitaxel or a bleomycin/vincristine combination, based on local guidelines. The …
Matched conditions: KAPOSI SARCOMA
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:49 UTC